PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Results of DUTCH PEERS (TWENTE II) trial reported at TCT 2013

Comparison of 2 third-generation drug-eluting stents establishes comparable safety and efficacy; demonstrates non-inferiorityof newest zotarolimus-eluting stent

2013-10-31
(Press-News.org) Contact information: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Results of DUTCH PEERS (TWENTE II) trial reported at TCT 2013 Comparison of 2 third-generation drug-eluting stents establishes comparable safety and efficacy; demonstrates non-inferiorityof newest zotarolimus-eluting stent SAN FRANCISCO, CA – October 31, 2013 – Results of the DUTCH PEERS (TWENTE II) clinical trial demonstrate comparable safety and efficacy of two third-generation permanent polymer-based drug-eluting stents with low rates of adverse clinical events and establish the non-inferiority of the newest zotarolimus-eluting stent. The findings were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Third-generation permanent polymer-based drug-eluting stents (DES) with novel flexible designs were developed to improve stent deliverability in challenging anatomical lesions and to improve stent alignment within the vessel wall, while maintaining the anti-restenotic potential of newer generation DES systems. DUTCH PEERS (TWENTE II) follows the TWENTE trial, which was presented at TCT 2011 and examined second-generation drug-eluting stents with the same drugs and coatings but different stent platforms.

DUTCH PEERS was a multicenter, prospective, single-blinded, randomized controlled study in patients requiring percutaneous coronary interventions (PCI) with DES implantation. The study was performed in four PCI centers in the Netherlands (Thoraxcentrum Twente, Enschede; Rijnstate Hospital, Arnhem; Scheper Hospital, Emmen; Medical Center Alkmaar, Alkmaar). The primary endpoint was the composite target vessel failure (TVF) at one-year, defined as cardiac death, target vessel revascularization, or myocardial infarction (MI) attributable to the target vessel or not attributable to another vessel.

A total of 1,811 patients were randomly assigned to treatment with third-generation cobalt-chromium zotarolimus-eluting stents (906 patients; 1,205 lesions) or platinum-chromium everolimus-eluting stents (905 patients; 1,166 lesions). The study population (age 63.9±10.8 years, range 21󈟇 years; 73.0 percent male) was an "all-comers" population comprising 58.6 percent of patients with acute coronary syndromes (20.4 percent of all patients presented with an acute ST-elevation myocardial infarction). Of all 2,371 lesions, 65.7 percent were ACC/AHA lesion type B2/C. Follow-up data for 99.9 percent of the randomized patients were obtained.

TVF occurred in 6.1 percent (55/905) patients assigned to zotarolimus-eluting stents and 5.2 percent (47/905) assigned to everolimus-eluting stents. Non-inferiority of the zotarolimus-eluting stent was confirmed with an absolute risk difference of 0.88 percent (non-inferiority p-value = 0.006). There was also no significant between-group difference in individual components of the primary endpoint and other secondary clinical endpoints.

In both stent groups, definite-or-probable stent thrombosis rates were low. Definite-or-probable stent thrombosis rates were 0.6 percent (5/905) in the zotarolimus stent and 0.9 percent (8/905) in the everolimus stent (p value=0.40). Notably, there was no definite stent thrombosis beyond three months from stenting, reaffirming the safety of newer generation DES platforms.

"The clinical outcome of this trial was excellent – particularly when considering its high proportion of complex patients with acute myocardial infarction at presentation – and may represent a challenging touchstone of novel stents and scaffolds," said Clemens von Birgelen, MD PhD, the principal investigator of the trial. Dr. von Birgelen is Co-Director of the Department of Cardiology at Thoraxcentrum Twente and Professor of Cardiology at University of Twente in the Netherlands.

"Both permanent polymer-based stents were similarly efficacious and safe in treating all-comers with an excellent clinical outcome."

###

The DUTCH PEERS (TWENTE II) trial was equally funded by Boston Scientific and Medtronic. Dr. von Birgelen reported being a consultant to Abbott Vascular, Boston Scientific, and Medtronic. He has also received a travel grant from Biotronik and lecture fees from Biotronik and MSD.

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. CRF is the sponsor of the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Celebrating its 25th anniversary this year, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. For more information, visit http://www.crf.org and http://www.tctconference.com.

END



ELSE PRESS RELEASES FROM THIS DATE:

NASA sees Halloween Typhoon Krosa lashing Luzon, Philippines

2013-10-31
NASA sees Halloween Typhoon Krosa lashing Luzon, Philippines VIDEO: In this flyby animation of Oct. 30, NASA's TRMM satellite found precipitation falling at a rate ...

Pore formation in cell membranes linked to triggers of rheumatoid arthritis

2013-10-31
Pore formation in cell membranes linked to triggers of rheumatoid arthritis Discovery suggests new paths to treatments that stall or reverse protein modifications involved in the autoimmune disease Experiments by scientists at Johns Hopkins and in Boston have unraveled ...

A first step in learning by imitation, baby brains respond to another's actions

2013-10-31
A first step in learning by imitation, baby brains respond to another's actions Imitation may be the sincerest form of flattery for adults, but for babies it's their foremost tool for learning. As renowned people-watchers, babies often observe others demonstrate ...

Incurable brain cancer gene is silenced

2013-10-31
Incurable brain cancer gene is silenced Gene regulation technology increases survival rates in mice with glioblastoma Glioblastoma multiforme (GBM), the brain cancer that killed Sen. Edward Kennedy and kills approximately 13,000 Americans a year, is aggressive ...

Staph infections and eczema: What's the connection?

2013-10-31
Staph infections and eczema: What's the connection? New U-M-led research in animals pinpoints molecule from bacteria that may play key role in prompting skin inflammation &#8211 and could be a target for treatment ANN ARBOR, Mich. — For the millions ...

Listen up: Oysters may use sound to select a home

2013-10-31
Listen up: Oysters may use sound to select a home Oysters begin their lives as tiny drifters, but when they mature they settle on reefs. New research from North Carolina State University shows that the sounds of the reef may attract the young oysters, ...

Silent victims -- an epidemic of childhood exposure

2013-10-31
Silent victims -- an epidemic of childhood exposure Over 15 million children are exposed to intimate partner violence (IPV) each year, and the health consequences of this exposure are well-documented. The Institute of Medicine and the United States ...

Scientists call for action to tackle 'alarmingly' low survival of Kenyan women with cervical cancer

2013-10-31
Scientists call for action to tackle 'alarmingly' low survival of Kenyan women with cervical cancer Less than 7% of cervical cancer patients in Kenya are getting the optimum treatment needed to eradicate the disease, leading to unnecessary ...

Researchers discover that an exoplanet is Earth-like in mass and size

2013-10-31
Researchers discover that an exoplanet is Earth-like in mass and size CAMBRIDGE, MA -- In August, MIT researchers identified an exoplanet with an extremely brief orbital period: The team found that Kepler 78b, a small, intensely hot planet 400 light-years ...

Gladstone scientists identify molecular signals that rouse dormant HIV infection

2013-10-31
Gladstone scientists identify molecular signals that rouse dormant HIV infection Activating dormant virus key to purging viral infection and developing a cure for HIV/AIDS SAN FRANCISCO, CA—October 30, 2013—Perhaps the single greatest barrier to curbing the spread of HIV/AIDS ...

LAST 30 PRESS RELEASES:

Attitudes, not income, drive energy savings at home

The playbook for perfect polaritons

‘Disease in a dish’ study of progressive MS finds critical role for unusual type of brain cell

Solar-powered method lights the way to a ‘de-fossilized’ chemical industry

Screen time linked to lower academic achievement among Ontario elementary students

One-year outcomes after traumatic brain injury and early extracranial surgery in the TRACK-TBI Study

Enduring outcomes of COVID-19 work absences on the US labor market

Affirmative action repeal and racial and ethnic diversity in us medical school admissions

Cancer progression illuminated by new multi-omics tool

Screen time and standardized academic achievement tests in elementary school

GLP-1RA order fills and out-of-pocket costs by race, ethnicity, and indication

Study finds HEPA purifiers alone may not be enough to reduce viral exposure in schools

UVA Health developing way to ID people at risk of dangerous lung scarring even before symptoms appear

How can we know when curing cancer causes myocarditis?

Male infertility in Indian men linked to lifestyle choices and hormonal imbalances

An acoustofluidic device for sample preparation and detection of small extracellular vesicles

The advent of nanotechnology has ushered in a transformative era for oncology, offering unprecedented capabilities for targeted drug delivery and controlled release. This paradigm shift enhances thera

A prototype LED as thin as wallpaper — that glows like the sun

Transnational electoral participation of undocumented Mexican immigrants in the US

A new method to build more energy-efficient memory devices for a sustainable data future

Freely levitating rotor spins out ultraprecise sensors for classical and quantum physics

‘Chinese lantern’ structure shifts into more than a dozen shapes for various applications

Towards light-controlled electronic components

Tiny architects, titanic climate impact: scientists call for October 10 to become International Coccolithophore Day

Stress sensitivity makes suicidal thoughts more extreme and persistent among the university population

Lessons from Ascension’s shark troubles could help boost conservation

Fire provides long-lasting benefits to bird populations in Sierra Nevada National Parks

Menstrual cycle affects women’s reaction time but not as much as being active

Housing associations more effective than government in supporting unemployed in deprived areas

Biochar helps composting go greener by cutting greenhouse gas emissions

[Press-News.org] Results of DUTCH PEERS (TWENTE II) trial reported at TCT 2013
Comparison of 2 third-generation drug-eluting stents establishes comparable safety and efficacy; demonstrates non-inferiorityof newest zotarolimus-eluting stent